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Abstract
In humans, allelic variants in Toll-like receptors (TLRs) associate with several pathologies. However, the underlying cellular
and molecular mechanisms of this association remain largely unknown. Analysis of the human TLR9 promoter revealed that
the C allele of the rs5743836 polymorphism generates several regulatory sites, including an IL-6-responding element. Here,
we show that, in mononuclear cells carrying the TC genotype of rs5743836, IL-6 up-regulates TLR9 expression, leading to
exacerbated cellular responses to CpG, including IL-6 production and B-cell proliferation. Our study uncovers a role for the
rs5743836 polymorphism in B-cell biology with implications on TLR9-mediated diseases and on the therapeutic usage of
TLR9 agonists/antagonists.
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Introduction
Toll-like receptors (TLRs) are pattern recognition receptors
with a major role in activation and homeostasis of the immune
system upon pathogen recognition [1]. However, it has become
apparent that self-recognition through TLRs can also take place
and that this can play a role in sterile inflammation and
autoimmunity [2–3].
TLR9 activates the innate immune system upon recognition of
unmethylated CpG DNA motifs as ‘‘danger signals’’. In humans,
TLR9 is mainly expressed in plasmacytoid dendritic cells and B-
lymphocytes [4–5], playing a role on viral, fungal, mycobacterial
and Helicobacter pylori infections [6–10] and being implicated in the
pathogenesis of several autoimmune diseases [3,11].
Despite growing evidence of a strong link between deregulated
TLR9 responses and immune-mediated diseases, the underlying
cellular and molecular mechanisms remain largely unknown. In
psoriasis, uncontrolled expression of the antimicrobial peptide LL37
breaks innate immune tolerance by delivering self-DNA to TLR9-
containing endosomes, causing TLR9-mediated type I interferon
production that drives skin inflammation [3,11]. Other mechanisms
linking TLR9 deregulation and disease may involve TLR9 gain-of-
function due to transcriptional deregulation. We and others have
shown that the C allele of the single nucleotide polymorphism (SNP)
rs5743836 (T-1237C) in TLR9, known to display minor allele
frequencies ranging from 0.02 to 0.38 across distinct ethnicities,
predisposes to non-Hodgkin [12] and Hodgkin lymphoma [13], as
well as to several autoimmune and chronic inflammatory diseases,
including asthma [14] and Crohn’s disease [15].
In light of TLR9 relevance in disease, synthetic oligodeoxynu-
cleotides that specifically inhibit or activate TLR9 have been
developed [16]. These compounds can potentially be used in
infectious diseases, allergy/asthma and cancer therapy to either
block TLR9 self-recognition or stimulate the immune response in
conditions of immune tolerance. Given the highly promising
effects of CpG-based therapy, understanding the biological and
functional impact of TLR9 genetic variability is pertinent as it will
certainly contribute to anticipate potential side-effects associated
with TLR9 agonist/antagonist therapy.
Here, we report that the C allele of rs5743836 introduced a new
IL-6-dependent transcription factor binding site in the TLR9
promoter. Peripheral blood mononuclear cells (PBMCs) harboring
the TC genotype of rs5743836 show higher expression of both
TLR9 and IL-6 and increased B-cell proliferation in response to
CpG, functionally dependent on IL-6 signaling. Our findings not
only contribute to a better understanding of the functional impact
of TLR9 overexpression, but also raise important questions on the
therapeutic usage of CpGs in the context of the immunogenetic
profile of the patient.
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Results and Discussion
The C allele of rs5743836 introduces a functional IL-6-
responsive element in the TLR9 promoter
Several SNPs in TLR9 have been associated with increased risk
for immune-mediated diseases (International HapMap Project;
http://hapmap.ncbi.nlm.nih.gov/). We hypothesized that some of
these SNPs might alter the transcriptional regulation of TLR9,
leading to inappropriate gain- or loss-of-function. To test this, we
screened the transcription factor-binding profile of the human
TLR9 promoter for alterations introduced by known SNPs. In silico
analysis revealed that the C allele of rs5743836 generated several
novel binding sites for different transcription factors (Fig. 1A). The
potential regulatory transcription factor-binding motif with the
highest score corresponded to an interleukin-6 (IL-6) response
element (IL-6 RE) at position -1238 to -1234 with the consensus
sequence TTCCAG (Fig. 1A). This type II IL-6 consensus motif
has already been shown to play a key role on STAT3
transactivation of the human c-fibrinogen promoter triggering
up-regulation [17], but was never studied in the context of TLR9.
To investigate whether the TLR9 promoter carrying the C allele
of rs5743836 was regulated by IL-6, we measured the ectopic
expression of luciferase under control of the TLR9 promoter
sequence with either the T or C allele in transiently transfected B-
cells. As shown in Fig. 1B, upon stimulation with recombinant
human IL-6, cells carrying the variant construct displayed a
significant 3.2-fold increase in luciferase activity (p,0.001), whereas
this effect was not observed for the wild-type construct. This result
indicates that rs5743836 regulates the transcriptional activity of the
TLR9 promoter in an IL-6-dependent manner.
We next evaluated whether the C allele of rs5743836 in its
native chromosomal context also led to an IL-6-dependent
increase in TLR9 mRNA expression. For this, PBMCs with the
TT or TC genotypes were stimulated with increasing doses of
recombinant IL-6. We observed that only TC PBMCs responded
to the presence of IL-6 with increased TLR9 expression, in a dose-
dependent manner (Fig. 1C).
In addition, we observed that, as compared to TT, unstimulated
TC PBMCs displayed an approximately 2.4-fold increase in the
basal transcription of TLR9 (p = 0.008) (Fig. 1C), due to basal
production of IL-6 (Fig. 1D). Interestingly, the neutralization of
endogenous IL-6 resulted in a decreased TLR9 expression to levels
similar to those of TT cells (Fig. 1E). Overall, our data point
towards a major impact of the rs5743836 polymorphism on the
transcriptional regulation of TLR9 and support an IL-6-dependent
modulation of TLR9 gene expression.
Figure 1. IL-6 increases the activity of the TLR9 promoter carrying the C allele of rs5743836. (A) In silico analysis of the fragment of the
TLR9 promoter containing the T/C substitution using the TESS interface. La, log-likelihood score, Lq, a measure of the goodness-of-fit of the DNA
sequence to the consensus binding motif. (B) Luciferase reporter assay of Raji B cells transfected with plasmid vectors containing the luciferase gene
under the control of a 3.2 kb fragment of the promoter sequence carrying the T or C allele. After transfection, cells were left untreated or stimulated
with IL-6 (n = 3). (C) IL-6 dose-dependent stimulation of either TT (n = 27) or TC (n = 25) PBMCs. Cells were left untreated or stimulated with increasing
doses of recombinant IL-6. TLR9 mRNA expression levels were determined by real-time PCR. (D) IL-6 secretion by of either TT (n = 21) or TC (n = 17)
PBMCs. IL-6 in untreated cells was quantified by ELISA. (E) TLR9 expression in TT (n = 21) or TC (n = 17) PBMCs in IL-6-neutralizing conditions. Cells
were cultured with an anti-IL-6 antibody and TLR9 mRNA expression was determined by real-time PCR. Results shown are the mean 6 SD.
doi:10.1371/journal.pone.0028256.g001
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B cells harboring the TC genotype of rs5743836 show
increased proliferation upon CpG stimulation
To investigate whether the transcriptional upregulation of
TLR9 caused by the TC genotype of rs5743836 led to a gain-of-
function phenotype, TC PBMCs were stimulated with CpG.
Although IL-6 was produced upon TLR9 activation regardless of
the genotype, its production was higher in TC cells (p = 0.009)
(Fig. 2A). We next questioned whether in TC cells, CpG
stimulation, via IL-6 production, could lead to further up-
regulation of TLR9 transcription and thus to a perpetuation loop
of TLR9-mediated mechanisms. We stimulated PBMCs with
CpG and measured TLR9 transcription. We observed that CpG
induced a strong increase in TLR9 expression in TC (p,0.0001),
but not TT cells (Fig. 2B). This up-regulation of TLR9 expression
was abrogated by neutralizing the biological activity of IL-6
(Fig. 2B). In the presence of a TLR9 antagonist (TTAGGG), the
up-regulation of TLR9 expression upon CpG stimulation was
only partially reverted (Fig. 2B), probably due to the basal
presence of IL-6 (Fig. 1C and 1D). Altogether, our data suggest
that PBMCs carrying the TC genotype of rs5743836 are more
responsive to CpG stimulation and that this effect is most likely
perpetuated by increased TLR9 transcription and IL-6 produc-
tion.
Taking into consideration that B-cells constitute the major
cellular population expressing TLR9 within PBMCs (4), and given
that rs5743836 affected the levels of both TLR9 and IL-6 in
response to CpG, we investigated whether the presence of this
variant impacted B-cell proliferation. To answer this question,
PBMCs were stimulated with CpG, and CD19+ cell proliferation
was assessed. CD19+ cell proliferation induced by CpG was
significantly higher in TC cells as compared to TT cells (48.5%
vs. 22.8%, respectively; p,0.0001) and was abrogated by co-
incubation with a TLR9 antagonist (Fig. 2C). In line with the fact
that TLR9 signaling is stronger in cells overexpressing TLR9 [4,18],
and that IL-6 mediates TLR9 up-regulation in TC cells,
neutralization of IL-6 abrogated the increased proliferation of these
cells in response to CpG to levels similar to those of wild-type cells
(Fig. 2C). Again, our data support an amplification loop mediated
by CpG and IL-6 that culminates with a deregulated TLR9
signaling.
Altogether, our data indicate that TLR9 signaling is amplified
by a positive feedback loop through IL-6 in TC carriers of
rs5743836 (Fig. 3), an example on how functional genomic
studies may give insights on the regulation of gene activity under
different situations, and can contribute to our knowledge on
molecular and genetic mechanisms underlying disease suscepti-
bility. In summary, we present evidences that shed light on how a
certain genetic profile associated with excessive immune/
inflammatory activation may contribute to human disease. Our
findings not only identify a new regulatory element in the
promoter region of TLR9, leading to its transcriptional activation
through the IL-6 signaling pathway, with implications on cellular
physiology, but also demonstrate the possibility to abolish the
cellular effects of this SNP thus strongly supporting new potential
individually-targeted treatments. In addition to the broad
implications of our study in immune-mediated diseases, another
important issue raised by our data is related to the therapeutic
application of CpG-based compounds. As we now show,
individual genetic variations can affect the outcome of the
TLR9 signalling pathway. Re-interpreting CpG therapy trial
results, taking into consideration the genotype of the participants,
may therefore be of interest, since the global results may have
been masked by the presence of the relatively common rs5743836
SNP. Ultimately, the therapeutic applications of CpG should be
individually tailored as they may prove to be either detrimental or
more effective for individuals harbouring the TC genotype of
rs5743836.
Figure 2. Human PBMCs carrying the TC genotype of
rs5743836 stimulated via TLR9 show increased transcription
of TLR9 and enhanced B-cell proliferation. (A) TC PBMCs secrete
higher amounts of IL-6 upon activation of TLR9 with CpG ODN 2006. IL-
6 production was quantified by ELISA in the supernatants of TT (n = 22)
or TC (n = 17) PBMCs following culture with CpG. (B) TLR9 activation of
TC cells by CpG ODN 2006 increases TLR9 gene expression.
Quantification of TLR9 mRNA expression in either TT (n = 24) or TC
(n = 27) PBMCs cultured with: CpG ODN 2006 (0.05 mM); CpG ODN 2006
and anti-IL-6 antibody; CpG ODN 2006 and the TLR9 antagonist CpG
ODN TTAGGG in a 1:2 ratio. (C) Proliferation of CD19+ cells was assessed
by CFSE dilution in PBMCs with different rs5743836 genotypes, TT
(n = 40) and TC (n = 33), left untreated or stimulated with: CpG ODN
2006 (0.05 mM); CpG ODN 2006 and anti-IL-6 antibody; CpG ODN 2006
and CpG ODN TTAGGG in a 1:2 ratio. Results shown are the means 6
SD.
doi:10.1371/journal.pone.0028256.g002
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Materials and Methods
Ethics Statement
Study protocols were approved by Instituto Portugueˆs de
Oncologia de Lisboa, Francisco Gentil, EPE and Instituto
Portugueˆs de Oncologia de Coimbra, Francisco Gentil, EPE,
Portugal. All study participants provided written informed consent
prior to biospecimen collection.
In silico analysis of TLR9 promoter allelic variants
Allelic variants within TLR9 promoter were analyzed to predict
alterations in transcription factor-binding sites, using the TESS
interface (http://www.cbil.upenn.edu/cgi-bin/tess/). Parameters
used in motif prediction included La, log-likelihood score, and Lq,
measure of the goodness-of-fit of the DNA sequence to the
consensus binding motif; the best possible Lq value was 1.000.
Plasmid constructs and mutagenesis
A plasmid vector containing the luciferase gene under control of
the wild-type TLR9 promoter [19] was used for site-directed PCR
mutagenesis. Briefly, the substitution at position -1237 was
introduced by all-round PCR amplification using the primers 59-
TATGAGACTTGGGGGAGTTTC CAGGCAGAGGGAA-
CAGCACA-39 and 59-TGTGCTGTTCCCTCTGCCTGGA-
AACTCCCCCAAGTCTCATA-39. The correct construct was
confirmed by direct sequencing.
Cell lines and cell culture
The Raji B-cell line (ATCC; wild-type for rs5743836) were
cultivated in RPMI culture medium with 2 mM L-glutamine,
1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES,
1.0 mM sodium pyruvate and 10% fetal bovine serum - FBS]
without antibiotics.
Transient transfection and luciferase reporter gene assay
Raji cells (56106 cells/ml) were transfected using the Micro-
porator system (NanoEnTek Inc, Korea) following manufacturer
instructions. Transfection efficiency was normalized by co-
transfection of 0.5 mg of the control b-galactosidase vector
(pCMV-bgal). After recovery, human recombinant IL-6
(100 ng/ ml) was added to 16106 cells for 12 hours. Cells were
lysed with 16Passive Lysis Buffer (Promega, USA) and luciferase
activity was measured using the Luciferase Assay System
(Promega). Firefly, luciferase activity was normalized against b-
galactosidase activity, determined with the b-galactosidase En-
zyme Assay System (Promega). Data are expressed as relative
luciferase units.
PBMC culture
PBMCs of healthy blood donors were isolated using Histopa-
que-1077 (Sigma, USA). Given the very low frequency of
individuals with the CC genotype, PBMCs with TT and TC
Figure 3. Proposed model of the effect of rs5743836 in B-lymphocyte activation and proliferation. TLR9 activation by CpG DNA induces
the production of IL-6, which upon binding to its receptor, promotes translocation of STAT3 to the nucleus. This transcription factor can bind to and
trans-activate promoters containing STAT3 binding elements, thus initiating a specific transcriptional program. In cells harboring the TC genotype of
rs5743836, STAT3 will bind to a new IL-6 RE site, created by the T/C substitution within the TLR9 promoter. As a result, TLR9 expression increases in
response to IL-6. Therefore, in these cells, a loop of TLR9/IL-6 signaling amplification is created, leading to a deregulation in B-cell activation and
proliferation upon CpG stimuli. Of note, the IL-6 needed to generate this loop may be TLR9-independent.
doi:10.1371/journal.pone.0028256.g003
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genotypes were used throughout. Cell viability was determined
using trypan blue exclusion. 16106 PBMC/ml were seeded in 24-
well flat bottom plates and cultivated for 5 days with 0.05 mM
CpG ODN 2006 (59-TCGTCGTTTTGTCGTTTTGTCGTT-
39) (InvivoGen, France). Cells either left unstimulated or
stimulated with control CpG ODN 2006 (59-TGCTGCT-
TTTGTGCTTTTGTGCTT-39) (InvivoGen) were included as
controls throughout the study.
CFSE proliferation assay
PBMCs (2.56106 cells/ml) were resuspended in serum-free
Hank’s Balanced Salt Solution (HBSS) and labeled with CFSE
(Molecular Probes, USA) at a concentration of 5 mM. Labeling
was quenched by the addition of 1/5 of the total volume of FBS.
After washing with complete RPMI medium, cells (26106 cells/
ml) were cultured in 24-well plates for 5 days in medium alone or
with CpG ODN plus or minus rabbit anti-IL-6 antibody (Sigma-
.Aldrich) or CpG antagonist. Cells were washed, resuspended in
staining buffer (0.5% BSA, 0.04% EDTA, 0.05% sodium azide in
PBS) and stained with APC-conjugated anti-human CD19 (Becton
Dickinson, San Jose, CA, USA) and analyzed on a BD
FACSCalibur flow cytometer (Becton Dickinson).
Real-time RT-PCR
Total RNA was isolated using the RNeasy Mini Kit (Qiagen,
Germany) and reverse-transcribed using the iScript cDNA
Synthesis Kit (Bio-Rad, France). For RT-PCR, 1 ml of cDNA
was used as template using the QuantiTect Sybr Green PCR Kit
(Qiagen). RT-PCR primers were as follows: b-actin, sense: 59-
GCCGTCTTCCCCTCCATCGTG-39, antisense: 59-GGAGC-
CACACGCAGCTCATTGTAGA-39; TLR9, sense: 59-CAGCA-
GCTCTGCAGTACGTC-39, antisense: 59-CTCAGGCCTTG-
GAAGA AGTG-39. RT-PCR was conducted on a LightCycler
System (Roche Applied Science, Switzerland) and the thermal
cycling conditions included 50 cycles of 10 s at 95 uC, 20 s at 55
uC, and 20 s at 72 uC, after a 15-min initial step of enzyme
activation at 95 uC, a melting step of 55–95 uC (0.5 uC/s) and a
final cooling step at 40 uC. Expression of b-actin was used as
internal control. Expression of TLR9 is indicated as n-fold increase
relative to the level of TLR9 expression in untreated wild-type
cells, using the 2-DDCt method.
IL-6 quantification
IL-6 was quantified in supernatants from PBMC cultures either
in untreated conditions or stimulated for 5 days with CpG ODN
2006 using human IL-6 Quantikine ELISA kit (R&D Systems,
Minneapolis, MN, USA).
Statistical analysis
Data were analyzed by GraphPad Prism 4.03 program (USA).
Unpaired Student’s T-test with Bonferroni’s adjustment was used
to determine statistical significance (p,0.05). All experiments were
performed at least in triplicate and repeated at least twice.
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